Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a publicly traded Healthcare sector company. As of May 21, 2026, CRBP trades at $9.93 with a market cap of $184.35M and a P/E ratio of -1.68. CRBP moved +6.56% today. Year to date, CRBP is +24.27%; over the trailing twelve months it is +28.53%. Its 52-week range spans $4.64 to $22.20. Analyst consensus is strong buy with an average price target of $40.78. Rallies surfaces CRBP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Corbus Appoints Ex-BMS Oncology Head Pfeiffenberger to Drive CRB-701 Registration Study: Corbus Pharmaceuticals has named Brent Pfeiffenberger, former Neogene COO and ex-Bristol Myers Squibb Oncology head, to its board to strengthen commercial and development strategy ahead of a CRB-701 registrational trial in second-line head and neck cancer this summer. Updated CRB-701 Phase 1/2 data will be unveiled at ASCO’s May 29 – June 2 meeting.
| Metric | Value |
|---|---|
| Price | $9.93 |
| Market Cap | $184.35M |
| P/E Ratio | -1.68 |
| EPS | $-5.74 |
| Dividend Yield | 0.00% |
| 52-Week High | $22.20 |
| 52-Week Low | $4.64 |
| Volume | 1.29K |
| Avg Volume | 0 |
| Revenue (TTM) | $5.25M |
| Net Income | $-84.53M |
| Gross Margin | 0.00% |
10 analysts cover CRBP: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $40.78.